Pivoting to telemedicine in a single-day multidisciplinary liver tumor clinic during COVID-19 : the Texas Liver Tumor Center experience
Cancer guidelines recommend that all patients with hepatocellular carcinoma (HCC) have an evaluation by a multidisciplinary team to assess liver health, stage the cancer, and discuss treatment and palliative care options. Coronavirus disease 2019 (COVID-19) had a catastrophic impact on patients with cancer resulting in increased disease burden due to late diagnosis and treatment delays. Late diagnosis has highlighted the need for the early intervention of palliative care for patients with HCC. Conversion to telemedicine has been essential to caring for patients with all stages of cancer without added delays. Texas Liver Tumor Center (TLTC) offers patients with liver cancer at any stage a single-day multidisciplinary evaluation with tumor board review facilitating the early integration of treatment and palliative care services. National Comprehensive Cancer Network (NCCN) guidelines support increasing and improving access to palliative care. TLTC allows for the early integration of palliative care within a 1-day clinic model with an incorporated tumor board. This unique model of patient care decreases the burden of separate patient visits, may expedite the time from diagnosis to first treatment, facilitates the early intervention of palliative care specialists, and allows for optimal screening for clinical trials. In this review, we will provide an overview of the current multidisciplinary models of care for HCC and describe the successful pivot of TLTC from a fully in-person single-day multidisciplinary clinic with a multidisciplinary tumor board (MDTB) to a fully virtual experience, thereby maintaining access to this unique clinical model of patient care during the COVID-19 pandemic. The ability to pivot from in-person clinical visits to completely virtual visits increases patient access to care and enables more physicians to participate. Areas for future study include the impact on patient experience, clinical outcomes, and cost-effectiveness of this high-resource model.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Annals of palliative medicine - 12(2023), 6 vom: 11. Nov., Seite 1310-1317 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Crow, Katherine S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coronavirus disease 2019 (COVID-19) |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 16.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.21037/apm-23-357 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364448768 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364448768 | ||
| 003 | DE-627 | ||
| 005 | 20231227133209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/apm-23-357 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1230.xml |
| 035 | |a (DE-627)NLM364448768 | ||
| 035 | |a (NLM)37953220 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Crow, Katherine S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pivoting to telemedicine in a single-day multidisciplinary liver tumor clinic during COVID-19 |b the Texas Liver Tumor Center experience |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 16.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Cancer guidelines recommend that all patients with hepatocellular carcinoma (HCC) have an evaluation by a multidisciplinary team to assess liver health, stage the cancer, and discuss treatment and palliative care options. Coronavirus disease 2019 (COVID-19) had a catastrophic impact on patients with cancer resulting in increased disease burden due to late diagnosis and treatment delays. Late diagnosis has highlighted the need for the early intervention of palliative care for patients with HCC. Conversion to telemedicine has been essential to caring for patients with all stages of cancer without added delays. Texas Liver Tumor Center (TLTC) offers patients with liver cancer at any stage a single-day multidisciplinary evaluation with tumor board review facilitating the early integration of treatment and palliative care services. National Comprehensive Cancer Network (NCCN) guidelines support increasing and improving access to palliative care. TLTC allows for the early integration of palliative care within a 1-day clinic model with an incorporated tumor board. This unique model of patient care decreases the burden of separate patient visits, may expedite the time from diagnosis to first treatment, facilitates the early intervention of palliative care specialists, and allows for optimal screening for clinical trials. In this review, we will provide an overview of the current multidisciplinary models of care for HCC and describe the successful pivot of TLTC from a fully in-person single-day multidisciplinary clinic with a multidisciplinary tumor board (MDTB) to a fully virtual experience, thereby maintaining access to this unique clinical model of patient care during the COVID-19 pandemic. The ability to pivot from in-person clinical visits to completely virtual visits increases patient access to care and enables more physicians to participate. Areas for future study include the impact on patient experience, clinical outcomes, and cost-effectiveness of this high-resource model | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Telemedicine | |
| 650 | 4 | |a coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a hepatocellular carcinoma (HCC) | |
| 650 | 4 | |a multidisciplinary care | |
| 650 | 4 | |a palliative care | |
| 700 | 1 | |a Poordad, Fred F |e verfasserin |4 aut | |
| 700 | 1 | |a Halff, Glenn A |e verfasserin |4 aut | |
| 700 | 1 | |a Cigarroa, Francisco G |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Infante, Irma V |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, Sukeshi Patel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of palliative medicine |d 2012 |g 12(2023), 6 vom: 11. Nov., Seite 1310-1317 |w (DE-627)NLM219739978 |x 2224-5839 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:6 |g day:11 |g month:11 |g pages:1310-1317 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/apm-23-357 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 6 |b 11 |c 11 |h 1310-1317 | ||